Clinical Trial Update: A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase III clinical trial is evaluating Purinostat Mesylate for injection in patients with recurrent or refractory diffuse large B-cell lymphoma and is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Purinostat Mesylate for Injection (Purinostat Mesylate)

Snippet

Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd | Conditions: Recurrent and Refractory Diffuse Large B-cell Lymphoma | Phase 3 | Status: RECRUITING